Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Clinical trial NCT06058793 · COMPLETED
Trial details
- NCT number
- NCT06058793
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-13
- Primary completion
- 2025-12-12
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.